Read More Pharma Industry News Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC? Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Discover what this means for trial execution and survival outcomes. bySoujanya RaviMarch 26, 2026